title: A new era of clinical dopamine transporter imaging using 123I-FP-CIT.
abstract: (123)I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane ((123)I-FP-CIT) was approved for clinical use in 2011 by the Food and Drug Administration. (123)I-FP-CIT is a radioligand for brain dopamine transporter (DAT) imaging that is useful for the differential diagnosis of Parkinson disease (PD) and other diseases that mimic PD. The sensitivity and specificity of (123)I-FP-CIT SPECT for PD diagnosis are more than 90% and equivalent to those of other DAT SPECT methods. In the near future, the clinical indications of DAT imaging are expected to be broadened; for example, including treatment response assessment, disease progression monitoring, and early diagnosis of premotor PD in each individual patient.
authors.affiliation: Department of Nuclear Medicine, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.
authors.forename: Eunkyung
authors.initials: E
authors.lastname: Park
mesh_terms: D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D057054:Molecular Imaging / Q000191:economics / Q000379:methods*; D017072:Neostriatum / Q000378:metabolism; D020734:Parkinsonian Disorders / Q000175:diagnosis / Q000378:metabolism; D014326:Tropanes / Q000378:metabolism
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane